<DOC>
	<DOCNO>NCT01605526</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1b study evaluate safety , pharmacokinetics efficacy RO5045337 combination doxorubicin patient soft tissue sarcoma . Cohorts patient receive escalate dos RO5045337 orally Days 1-5 ( 1-3 ) 28-day cycle combination doxorubicin 60 mg/m2 intravenously Day 1 cycle 6 cycle .</brief_summary>
	<brief_title>A Study RO5045337 Combination With Doxorubicin Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm soft tissue sarcoma Evaluable disease accord RECIST version 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Eligible doxorubicin therapy Acute toxicities prior antitumor therapy , surgery radiotherapy must resolve NCICTCAE Grade &lt; /= 1 prior start study Adequate bone marrow , hepatic renal function Patients stable CNS metastasis eligible Previous treatment limit dos doxorubicin Patients receive investigational commercial agent therapy administer intention treat malignancy ailment &lt; /= 28 day Day 1 dose study treatment History seizure disorder unstable CNS metastasis Severe and/or uncontrolled medical condition condition could affect participation study Pregnant breastfeed woman HIV positive patient currently receive combination antiretroviral therapy Patients know coagulopathy , platelet disorder history nondrug induce thrombocytopenia Patients receive oral parenteral anticoagulants/antiplatelet agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>